Target adverse event profiles for predictive safety in the post-market setting.

Clicks: 314
ID: 204882
2020
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #9 of 11 articles by views in clinical pharmacology and therapeutics

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
We improved a previous pharmacological target adverse-event profile model to predict adverse events on FDA drug labels at the time of approval. The new model uses more drugs and features for learning as well as a new algorithm. Comparator drugs sharing similar target activities to a drug of interest were evaluated by aggregating adverse events from the FDA Adverse Event Reporting System (FAERS), FDA drug labels, and medical literature. An ensemble machine learning model was used to evaluate FAERS case count, disproportionality scores, percent of comparator drug labels with a specific adverse event, and percent of comparator drugs with the reports of the event in the literature. Overall classifier performance was F1 of 0.71, area under the precision-recall curve of 0.78, and area under the receiver operating characteristic curve of 0.87. Target adverse-event analysis continues to show promise as a method to predict adverse events at the time of approval.
Reference Key
schotland2020targetclinical Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Schotland, Peter;Racz, Rebecca;Jackson, David B;Soldatos, Theodoros G;Levin, Robert;Strauss, David;Burkhart, Keith;
Journal clinical pharmacology and therapeutics
Year 2020
DOI
10.1002/cpt.2074
URL
Keywords
Machine learning Atrial fibrillation neural networks atrial fibrillation screening stroke prevention targeted screening

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.